Treatment of advanced XXXX / @entity4889 with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy.

@entity1 @entity4888 @entity8778 @entity404 @entity4889 @entity10043 @entity784 @entity8548 @entity9392 @entity10771 @entity1054
BACKGROUND: @entity10043 analogues [ @entity10771 (FAMP); @entity9392 and @entity8778 ) and extracorporeal photochemotherapy (ECP) have been suggested to be active agents in advanced @entity784 ( @entity784 ) @entity1 . OBJECTIVES: To explore further the clinical efficacy and safety of FAMP monochemotherapy in advanced @entity784 and to evaluate if the sequential association of ECP to FAMP in selected @entity1 may improve the response rate (RR) and/or lengthen the remission duration. @entity1 AND METHODS: Forty-four @entity784 @entity1 [17 @entity4889 ( @entity4889 ); 26 @entity4888 ( @entity4888 ), stage IIB-IV or with peripheral blood involvement; one @entity4888 associated with @entity8548 ( @entity8548 )] were enrolled in this pilot cohort study. All the @entity1 received FAMP 25 mg m(-2) 5 days monthly; 19 @entity1 (43.2%) underwent ECP after FAMP was discontinued. The majority of @entity1 with erythrodermic @entity784 or peripheral blood involvement underwent the combined FAMP-ECP schedule. RESULTS: After a median follow-up of 4.2 years, the overall FAMP RR was 29.5% (13/44); a higher RR was obtained in @entity4889 (35.3%) than in @entity4888 @entity1 (25.9%). According to the treatment group, the RR of the FAMP-ECP group (63.2%) was significantly higher than that of the FAMP monotherapy group (24%; P=0.021). No statistically significant difference was found in @entity1054 ( @entity1054 ) or survival by therapy group, even if the @entity1054 of the @entity1 treated with the FAMP-ECP combination therapy was higher (median 13 vs. 7 months). A decrease or a normalization in the @entity404 +CD26- circulating subset was observed in responding @entity1 , paralleling the reduction in the circulating S  zary cells. CONCLUSIONS: FAMP confirms its clinical activity as a single agent in @entity4889 ; conversely, FAMP results do not compare favourably with other therapeutic approaches for advanced stage @entity4888 @entity1 . The sequential association of ECP after FAMP seems to increase the RR, even if future randomized studies are needed to confirm these results.
